Publicacións (23) Publicacións de Laura Gallego Yerga

2024

  1. Experimental structure based drug design (SBDD) applications for anti-leishmanial drugs: A paradigm shift?

    Medicinal Research Reviews, Vol. 44, Núm. 3, pp. 1055-1120

  2. Promising anti-proliferative indolic benzenesulfonamides alter mechanisms with sulfonamide nitrogen substituents

    European Journal of Medicinal Chemistry, Vol. 275

2023

  1. Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  2. Novel Tetrazole Derivatives Targeting Tubulin Endowed with Antiproliferative Activity against Glioblastoma Cells

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

  3. Novel amino analogs of the trimethoxyphenyl ring in potent colchicine site ligands improve solubility by the masked polar group incorporation (MPGI) strategy

    Bioorganic Chemistry, Vol. 131

  4. Nuevos antitumorales y antiparasitarios de naturaleza híbrida para la formación de nanopartículas

    IX Jornadas de investigadoras de Castilla y León

  5. Potent and Selective Benzothiazole-Based Antimitotics with Improved Water Solubility: Design, Synthesis, and Evaluation as Novel Anticancer Agents

    Pharmaceutics, Vol. 15, Núm. 6

2021

  1. Anticancer properties of indole derivatives as IsoCombretastatin A-4 analogues

    European Journal of Medicinal Chemistry, Vol. 223

  2. Application of ensemble pharmacophore-based virtual screening to the discovery of novel antimitotic tubulin inhibitors

    Computational and Structural Biotechnology Journal, Vol. 19, pp. 4360-4372

  3. Synthesis, self-assembly and anticancer drug encapsulation and delivery properties of cyclodextrin-based giant amphiphiles

    Carbohydrate Polymers, Vol. 252

2020

  1. Nanoparticle-mediated therapeutic compounds delivery to glioblastoma

    Expert Opinion on Drug Delivery, Vol. 17, Núm. 11, pp. 1541-1554

2019

  1. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors

    Molecules (Basel, Switzerland), Vol. 24, Núm. 23

2018

  1. Plasmid-Templated Control of DNA–Cyclodextrin Nanoparticle Morphology through Molecular Vector Design for Effective Gene Delivery

    Chemistry - A European Journal, Vol. 24, Núm. 15, pp. 3825-3835

2017

  1. Docetaxel-loaded nanoparticles assembled from β-cyclodextrin/calixarene giant surfactants: Physicochemical properties and cytotoxic effect in prostate cancer and glioblastoma cells

    Frontiers in Pharmacology, Vol. 8, Núm. MAY

  2. Molecular determinants for cyclo-oligosaccharide-based nanoparticle-mediated effective siRNA transfection

    Nanomedicine, Vol. 12, Núm. 13, pp. 1607-1621

2015

  1. Cyclodextrin- and calixarene-based polycationic amphiphiles as gene delivery systems: A structure-activity relationship study

    Organic and Biomolecular Chemistry, Vol. 13, Núm. 6, pp. 1708-1723

  2. Host-Guest-Mediated DNA Templation of Polycationic Supramolecules for Hierarchical Nanocondensation and the Delivery of Gene Material

    Chemistry - A European Journal, Vol. 21, Núm. 34, pp. 12093-12104

2014

  1. Dynamic self-assembly of polycationic clusters based on cyclodextrins for pH-sensitive DNA nanocondensation and delivery by component design

    Chemistry - A European Journal, Vol. 20, Núm. 22, pp. 6622-6627

  2. Glycoligand-targeted core–shell nanospheres with tunable drug release profiles from calixarene–cyclodextrin heterodimers

    Chemical Communications, Vol. 50, Núm. 56, pp. 7440-7443

  3. Glycotargeted self-assembled nanocarriers from calixarene-cyclodextrin heterodimers for site-specific delivery of docetaxel

    XI Carbohydrate Symposium